| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
480.52(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.86 - $18.69 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 13.4 |
| Insider 3/6 Months : 14 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the U.S. Food and Drug Administration for the treatment, in combination with Granulocyte-Macrophage Colony-Stimulating Factor of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
558,056 |
762,731 |
| Total Buy Value |
$0 |
$0 |
$3,530,830 |
$5,499,522 |
| Total People Bought |
0 |
0 |
2 |
3 |
| Total Buy Transactions |
0 |
0 |
14 |
17 |
| Total Shares Sold |
92,351 |
249,644 |
399,644 |
399,644 |
| Total Sell Value |
$1,118,618 |
$2,239,854 |
$3,035,237 |
$3,035,237 |
| Total People Sold |
2 |
4 |
4 |
4 |
| Total Sell Transactions |
4 |
10 |
12 |
12 |
| End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lisby Steen |
SVP & CHIEF SCIENTIFIC OFFICER |
• – – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
17,800 |
|
- |
|
| Kruse Bo |
EVP, CFO, Secry & Treas. |
• – – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
11,700 |
192,777 |
|
- |
|
| Wilms Joris |
SVP & CHIEF OPERATING OFFICER |
• – – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
17,800 |
|
- |
|
| Smith Susan Laura |
SVP & CHIEF COMMERCIAL OFFICER |
• – – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
17,800 |
|
- |
|
| Lund-Hansen Torben |
SVP & CHIEF TECHNICAL OFFICER |
• – – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
17,800 |
|
- |
|
| Gad Thomas |
See remarks |
• • – |
2023-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
40,500 |
90,500 |
|
- |
|
| Rajah Vignesh |
SVP & CMO |
• – – |
2022-11-15 |
4 |
B |
$4.92 |
$5,884 |
I/I |
1,195 |
4,266 |
1.99 |
-27% |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2022-02-22 |
4 |
AS |
$7.85 |
$31,400 |
D/D |
(4,000) |
181,077 |
|
94% |
|
| Gad Thomas |
See remarks |
• • – |
2022-02-09 |
4 |
S |
$6.96 |
$447,117 |
I/I |
(64,276) |
565,032 |
|
-86% |
|
| Gad Thomas |
See remarks |
• • – |
2022-02-08 |
4 |
S |
$7.01 |
$882,891 |
I/I |
(125,863) |
629,308 |
|
-66% |
|
| Gad Thomas |
See remarks |
• • – |
2022-02-07 |
4 |
S |
$7.59 |
$691,180 |
I/I |
(91,031) |
755,171 |
|
-44% |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas |
• – – |
2022-02-04 |
4 |
AS |
$7.97 |
$31,880 |
D/D |
(4,000) |
185,077 |
|
50% |
|
| Gad Thomas |
See remarks |
• • – |
2022-02-04 |
4 |
S |
$7.70 |
$778,531 |
I/I |
(101,104) |
846,202 |
|
-50% |
|
| Gad Thomas |
See remarks |
• • – |
2022-02-03 |
4 |
S |
$7.90 |
$277,027 |
I/I |
(35,060) |
947,306 |
|
-42% |
|
| Gad Thomas |
See remarks |
• • – |
2022-02-01 |
4 |
AS |
$10.15 |
$81,161 |
D/D |
(8,000) |
50,000 |
|
22% |
|
| Gad Thomas |
See remarks |
• • – |
2022-02-01 |
4 |
OE |
$2.00 |
$16,000 |
D/D |
8,000 |
58,000 |
|
- |
|
| Gad Thomas |
See remarks |
• • – |
2022-01-24 |
4 |
S |
$10.07 |
$936,412 |
I/I |
(88,055) |
982,366 |
|
-16% |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2022-01-24 |
4 |
AS |
$9.84 |
$39,360 |
D/D |
(4,000) |
189,077 |
|
16% |
|
| Gad Thomas |
See remarks |
• • – |
2022-01-21 |
4 |
S |
$10.51 |
$755,815 |
I/I |
(70,318) |
1,070,421 |
|
-24% |
|
| Gad Thomas |
See remarks |
• • – |
2022-01-20 |
4 |
S |
$11.33 |
$1,277,289 |
I/I |
(112,767) |
1,140,739 |
|
-13% |
|
| Gad Thomas |
See remarks |
• • – |
2022-01-19 |
4 |
AS |
$10.89 |
$756,092 |
I/I |
(69,414) |
1,253,506 |
|
10% |
|
| Gad Thomas |
See remarks |
• • – |
2022-01-18 |
4 |
AS |
$11.46 |
$4,584 |
I/I |
(400) |
1,322,920 |
|
-1% |
|
| Gad Thomas |
See remarks |
• • – |
2022-01-18 |
4 |
AS |
$11.54 |
$92,314 |
D/D |
(8,000) |
50,000 |
|
-1% |
|
| Gad Thomas |
See remarks |
• • – |
2022-01-18 |
4 |
OE |
$2.00 |
$16,000 |
D/D |
8,000 |
58,000 |
|
- |
|
| Kruse Bo |
EVP, CFO, Secretary & Treas. |
• – – |
2022-01-04 |
4 |
AS |
$17.12 |
$68,480 |
D/D |
(4,000) |
193,077 |
|
-38% |
|
258 Records found
|
|
Page 3 of 11 |
|
|
0.06 (0.5%) 
